Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

Fangce WANG, Bing Li, Ping Li, Shiguang Ye, Lili Zhou, Wenjun Zhang, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2023-185161

Published: 2023

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6258.

https://doi.org/10.1182/blood-2023-180524

Published: 2023

Journal Articles

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

Ping Li, Wei Liu, Shiguang Ye, Lili Zhou, Judy Zhu, Jiaqi Huang, Jing Li, Shigui Zhu, Chengxiao Zheng, Kevin Zhu, Xin Yao, Hui Wan, Yihong Yao, Aibin Liang, Dehui Zou

Blood (2023) 142 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2023-181527

Published: 2023

Journal Articles

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Haiyan Jiang, Ping Li, Lili Zhou, Shiguang Ye, Xiu Luo, Yan Lu, Bin Xue, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6934.

https://doi.org/10.1182/blood-2023-188386

Published: 2023

Journal Articles

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Yuqin Song, Keshu Zhou, Lanfang Li, Aibin Liang, Yun Qin, Zhen Xia, Yongen Gu, Zisong Zhou, Alex Tian, Jun Zhu

Blood (2023) 142 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2023-178430

Published: 2023

Journal Articles

Paired Circulating Tumor DNA in Cerebrospinal Fluid and Peripheral Blood: Reliable Technology for Diagnosing and Monitoring Primary and Secondary Central Nervous Lymphoma

Xinyu Zhu, Bing Xiu, Jingjing Zhu, Zhi-Zhang Yang, Aibin Liang

Blood (2023) 142 (Supplement 1): 2994.

https://doi.org/10.1182/blood-2023-189100

Published: 2023

Journal Articles

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Bin Xue, Xiu Luo, Yifan Liu, Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2023-180500

Published: 2023

Journal Articles

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Bin Xue, Xiu Luo, Yifan Liu, Lili Zhou, Shiguang Ye, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2023-184885

Published: 2023

Journal Articles

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Jie Zhou, Wenjun Zhang, Baoqing Yang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2023) 142 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2023-181816

Published: 2023

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Shiguang Ye, Lili Zhou, Yan Lu, Xiu Luo, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2023-184765

Published: 2023

Journal Articles

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Yan Lu, Shiguang Ye, Lili Zhou, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2023-182763

Published: 2023

Journal Articles

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Lili Zhou, Yifan Liu, Shiguang Ye, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3137.

https://doi.org/10.1182/blood-2023-184352

Published: 2023

Journal Articles

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Bo Dai, Feng Wang, Ying Wang, Jiayan Zhu, Yunxuan Li, Tingting Zhang, Luyao Zhao, Li-Ling Wang, Wenhui GAO, Junmin Li, Aibin Liang, Hong-hu Zhu, Ke Li, Jiong Hu

Blood (2022) 140 (Supplement 1): 5924–5925.

https://doi.org/10.1182/blood-2022-156735

Published: 2022

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China

Ying Wang, Xudong Wei, Dongmei Yan, Cheng Zhang, Hongsheng Zhou, Chunrong Tong, Heng Mei, Jie Jin, Ting Niu, Aibin Liang, Jienan Ren, Yiping Deng, Wei Jin, Yi Feng, Lin Shi, Yongzeng Wang, Changting Haudenschild, Lulu Lv, Jianxiang Wang

Blood (2022) 140 (Supplement 1): 1598–1600.

https://doi.org/10.1182/blood-2022-165002

Published: 2022

Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4564–4565.

https://doi.org/10.1182/blood-2022-168610

Published: 2022

Journal Articles

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Blood (2022) 139 (23): 3376–3386.

https://doi.org/10.1182/blood.2021013733

Published: 2022

Includes: Supplemental data

Journal Articles

Complete Remissions to PD-1 Blockade in Combination with Reduced-Dose ICE Chemotherapy in Two Cases of Relapsed or Refractory Classical Hodgkin Lymphoma with Bulky Lung Involvement after Failed PD-1 Blockade

Bing Xiu, Bing Li, Xinyu Zhu, Gangfeng Xiao, Xiu Luo, Zhi-Zhang Yang, Aibin Liang

Blood (2021) 138 (Supplement 1): 4368.

https://doi.org/10.1182/blood-2021-147134

Published: 2021

Journal Articles

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-137826

Published: 2020

Journal Articles

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-138538

Published: 2020

NARROW

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Paired Circulating Tumor DNA in Cerebrospinal Fluid and Peripheral Blood: Reliable Technology for Diagnosing and Monitoring Primary and Secondary Central Nervous Lymphoma

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Complete Remissions to PD-1 Blockade in Combination with Reduced-Dose ICE Chemotherapy in Two Cases of Relapsed or Refractory Classical Hodgkin Lymphoma with Bulky Lung Involvement after Failed PD-1 Blockade

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only